Top

Osteoporosis International

Published in:

01-02-2012 | Original Article

Associations of total osteocalcin with all-cause and cardiovascular mortality in older men. The Health In Men Study

Authors: B. B. Yeap, S.A. P. Chubb, L. Flicker, K. A. McCaul, P. R. Ebeling, G. J. Hankey, J. P. Beilby, P. E. Norman

Published in: Osteoporosis International | Issue 2/2012

Abstract

Summary

In older men, both lower and higher total osteocalcin levels predict increased all-cause mortality, with comparable associations for cardiovascular and non-cardiovascular deaths. Differences in osteocalcin levels might influence glucose metabolism and thereby cardiovascular risk, or reflect changes in bone turnover thus representing a marker for poorer health outcomes.

Introduction

Reduced levels of total osteocalcin (TOC) are associated with adiposity, insulin resistance and type 2 diabetes, implying this bone-derived peptide might modulate cardiovascular risk. However, there are few longitudinal data relating TOC levels to survival. We examined associations of TOC level with all-cause and cardiovascular mortality in older men.

Methods

We conducted a prospective cohort study of community-dwelling men aged 70–89 years. Aliquots of plasma collected at baseline (2001–2004) were assayed for TOC. Incidence and causes of death to 31 December 2008 were ascertained using data linkage. Cox regression analyses were performed with adjustment for conventional cardiovascular risk factors.

Results

From 3,542 men followed for median 5.2 years there were 572 deaths (16.1%). Mortality was lowest in men with TOC levels in the second quintile (12.6%). In multivariate analyses, men with TOC in the lowest and highest quintiles of values had increased all-cause mortality (Q1 vs Q2: hazard ratio [HR], 1.36; 95% confidence interval 1.02–1.80 and Q5 vs Q2: HR, 1.53, 95% CI 1.18–1.98). Men with low TOC levels had similar HR for cardiovascular and non-cardiovascular deaths (Q1 vs Q2: HR, 1.35 and 1.30 respectively). Higher TOC levels predicted cardiovascular disease (CVD)-related mortality (Q5 vs Q2, HR, 1.69, 95% CI 1.09–2.64).

Conclusions

TOC predicts all-cause and CVD-related mortality in community-dwelling older men. However, the relationship is U shaped with men at both ends of the distribution at increased risk. Further investigation is required to clarify whether the underlying mechanisms involve altered bone turnover or relate specifically to the biological activity of osteocalcin.

Hauschka PV, Lian JB, Cole DE, Gundberg CM (1989) Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol Rev 69:990–1047PubMed

Gundberg CM, Nieman SD, Abrams S, Rosen H (1998) Vitamin K status and bone health: an analysis of methods for determination of undercarboxylated osteocalcin. J Clin Endocrinol Metab 83:3258–3266PubMedCrossRef

Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, Dacquin R, Mee PJ, McKee MD, Jung DY, Zhang Z, Kim JK, Mauvais-Jarvis F, Ducy P, Karsenty G (2007) Endocrine regulation of energy metabolism by the skeleton. Cell 130:456–469PubMedCrossRef

Ferron M, Hinoi E, Karsenty G, Ducy P (2008) Osteocalcin differentially regulates β cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci 105:5266–5270PubMedCrossRef

Shea MK, Gundberg CM, Meigs JB, Dallal GE, Saltzman E, Yoshida M, Jacques P, Booth SL (2009) γ-Carboxylation of osteocalcin and insulin resistance in older men and women. Am J Clin Nutr 90:1230–1235PubMedCrossRef

HwangY-C JI-K, Ahn KJ, Chung HY (2009) The uncarboxylated form of osteocalcin is associated with improved glucose tolerance and enhanced β-cell function in middle-aged male subjects. Diabetes Metab Res Rev 25:768–772CrossRef

Kanazawa I, Yamaguchi T, Yamauchi M, Yamamoto M, Kurioka S, Yano S, Sugimoto T (2009) Adiponectin is associated with changes in bone markers during glycemic control in Type 2 diabetes mellitus. J Clin Endocrinol Metab 94:3031–3037PubMedCrossRef

Kanazawa I, Yamaguchi T, Yamauchi M, Yamamoto M, Kurioka S, Yano S, Sugimoto T (2010) Serum undercarboxylated osteocalcin was inversely associated with plasma glucose level and fat mass in type 2 diabetes mellitus. Osteoporos Int. doi:10.1007/s00198-010-1184-7

Levinger I, Zebaze R, Jerums G, Hare DL, Selig S, Seeman E (2010) The effect of acute exercise on undercarboxylated osteocalcin in obese men. Osteoporos Int. doi:10.1007/s00198-010-1370-7 PubMed

10.

Im J-A, Yu B-P, Jeon JY, Kim S-H (2008) Relationship between osteocalcin and glucose metabolism. Clin Chim Acta 396:66–69PubMedCrossRef

11.

Kindblom JM, Ohlsson C, Ljunggren O, Karlsson MK, Tivesten A, Smith U, Mellstrom D (2009) Plasma osteocalcin is inversely related to fat mass and plasma glucose in elderly Swedish men. J Bone Miner Res 24:785–791PubMedCrossRef

12.

Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Kurioka S, Yano S, Sugimoto T (2009) Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes. J Clin Endocrinol Metab 94:45–49PubMedCrossRef

13.

Pittas AG, Harris SS, Eliades M, Stark P, Dawson-Hughes B (2009) Association between serum osteocalcin and markers of metabolic phenotype. J Clin Endocrinol Metab 94:827–832PubMedCrossRef

14.

Saleem U, Mosley TH, Kullo IJ (2010) Serum osteocalcin is associated with measures of insulin resistance, adipokine levels, and the presence of metabolic syndrome. Arterioscler Thromb Vasc Biol 30:1474–1478PubMedCrossRef

15.

Yeap BB, Chubb SAP, Flicker L, McCaul KA, Ebeling PR, Beilby JP, Norman PE (2010) Reduced serum total osteocalcin is associated with metabolic syndrome in older men through its association with hyperglycemia, waist circumference and serum triglycerides. Eur J Endocrinol 163:265–272PubMedCrossRef

16.

Saely CH, Aczel S, Marte T, Langer P, Hoefle G, Drexel H (2005) The Metabolic Syndrome, insulin resistance, and cardiovascular risk in diabetic and nondiabetic patients. J Clin Endocrinol Metab 90:5698–5703PubMedCrossRef

17.

Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Meigs JB, Bonadonna RC, Muggeo M (2007) Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in Caucasian subjects from the general population. Diab Care 30:318–324CrossRef

18.

Szulc P, Kaufman JM, Delmas PD (2007) Biochemical assessment of bone turnover and bone fragility in men. Osteoporos Int 18:1451–1461PubMedCrossRef

19.

Khosla S, Amin S, Orwoll E (2008) Osteoporosis in men. Endocr Rev 29:441–464PubMedCrossRef

20.

Cornier M-A, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, Van Pelt RE, Wang H, Eckel RH (2008) The metabolic syndrome. Endocr Rev 29:777–822PubMedCrossRef

21.

Norman PE, Flicker L, Almeida OP, Hankey GJ, Hyde Z, Jamrozik K (2009) Cohort profile: the Health In Men Study (HIMS). Int J Epidemiol 38:48–52PubMedCrossRef

22.

The Australian Diabetes, Obesity and Lifestyle Study (2000) Diabesity and associated disorders in Australia 2000. International Diabetes Institute, Melbourne

23.

Holman CD, Bass AJ, Rouse IL, Hobbs MS (1999) Population-based linkage of health records in Western Australia: development of a health services research linked database. Aust N Z J Public Health 23:453–459PubMedCrossRef

24.

Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chr Dis 40:373–383CrossRef

25.

Takahashi M, Kushida K, Nagano A, Inoue T (2000) Comparison of the analytical and clinical performance characteristics of an N-MID versus an intact osteocalcin immunoradiometric assay. Clin Chim Acta 294:67–76PubMedCrossRef

26.

Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496–509CrossRef

27.

Greenland S (1989) Modeling and variable selection in epidemiologic analysis. Am J Public Health 79:340–349PubMedCrossRef

28.

Fernandez-Real JM, Izquierdo M, Ortega F, Gorostiaga E, Gomez-Ambrosi J, Moreno-Navarrete JM, Fruhbeck G, Martinez C, Idoate F, Salvador J, Forga L, Ricart W, Ibanez J (2009) The relationship of serum osteocalcin to insulin secretion, sensitivity, and disposal with hypocaloric diet and resistance training. J Clin Endocrinol Metab 94:237–245PubMedCrossRef

29.

Wilson PW, D'Agostino RB, Parise H, Sullivan L, Meigs JB (2005) Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 112:3066–3072PubMedCrossRef

30.

Ferron M, Wei J, Yoshizawa T, Del Fattore A, DePinho RA, Teti A, Ducy P, Karsenty G (2010) Insulin signalling in osteoblasts integrates bone remodelling and energy metabolism. Cell 142:296–308PubMedCrossRef

31.

Fulzele K, Riddle RC, DiGirolamo DJ, Cao X, Wan C, Chen D, Faugere M-C, Aja S, Hussain MA, Bruning JC, Clemens TL (2010) Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. Cell 142:309–319PubMedCrossRef

32.

Sambrook PN, Chen CJ, March L, Cameron ID, Cumming RG, Lord SR, Simpson JM, Seibel MJ (2006) High bone turnover is an independent predictor of mortality in the frail elderly. J Bone Miner Res 21:549–555PubMedCrossRef

33.

Chen JS, Sambrook PN, March L, Cameron ID, Cumming RG, Simpson JM, Seibel MJ (2008) Hypovitaminosis D and parathyroid hormone response in the elderly: effects on bone turnover and mortality. Clin Endocrinol 68:290–298

34.

Kado DM, Browner WS, Blackwell T, Gore R, Cummings SR (2000) Rate of bone loss is associated with mortality in older women: a prospective study. J Bone Miner Res 15:1974–1980PubMedCrossRef

35.

Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L, on behalf of the INTERHEART Study Investigators (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364:937–952CrossRef

36.

Barr ELM, Tonkin AM, Welborn TA, Shaw JE (2009) Validity of self-reported cardiovascular disease events in comparison to medical record adjudication and a statewide hospital morbidity database: the AusDiab study. Intern Med J 39:49–53PubMedCrossRef

Title: Associations of total osteocalcin with all-cause and cardiovascular mortality in older men. The Health In Men Study
Authors: B. B. Yeap
S.A. P. Chubb
L. Flicker
K. A. McCaul
P. R. Ebeling
G. J. Hankey
J. P. Beilby
P. E. Norman
Publication date: 01-02-2012
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 2/2012
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-011-1586-1

At a glance: The STEP trials

Springer Medicine

Associations of total osteocalcin with all-cause and cardiovascular mortality in older men. The Health In Men Study

Abstract

Summary

Introduction

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2012

Treatment with acetaminophen/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg

Bone structure and turnover in type 2 diabetes mellitus

Epigenetic influences in the developmental origins of osteoporosis

Skeletal findings in children recently initiating glucocorticoids for the treatment of nephrotic syndrome

Relationships of muscle strength and bone mineral density in ambulatory children with cerebral palsy

Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass